Cross-labeling comments requested
This article was originally published in The Gray Sheet
FDA Office of Combination Products plans public meeting next spring or summer to gather input on cross-labeling of therapeutic products, according to OCP Director Mark Kramer. At a recent MDUFMA stakeholder meeting, the combo products chief identified cross-labeling as "a very sticky, complex regulatory issue," and said the 2005 meeting would help FDA generate feedback "with an eye toward rulemaking." OCP is considering guidance on the topic (1"The Gray Sheet" Oct. 25, 2004, p. 18). Under FDA's cross-labeling policy, items intended for use with a separate product may be required to carry dual labeling...
You may also be interested in...
An FDA intercenter task force is working to finalize the proposed rule governing "primary mode of action" for combination products
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.